Evidence map›Paper›PMID 41392765›Full record

ArticleBJPsych open2025

A proof-of-concept study: investigating the impact of COMT genotype and proline on negative symptoms in Alzheimer's disease.

James D Clelland, Hector W Cure, Ashley M Canizares, Julia H Anderson, Bimala Rawal, Sabrina A Wong, Nancy Kerner, Edward D Huey, Lawrence S Honig, Devangere P Devanand and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James D ClellandClinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, USA.ORCID https://orcid.org/0000-0002-2597-1140
Hector W CureDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Ashley M CanizaresDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Julia H AndersonDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Bimala RawalDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Sabrina A WongDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Nancy KernerDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Edward D HueyDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Lawrence S HonigGertrude H. Sergievsky Center, Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Devangere P DevanandDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0001-8597-1380
Catherine L ClellandDepartment of Psychiatry, Division of Geriatric Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-9364-3974

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Apathy in Alzheimer's Disease: Investigation of the Interaction between Proline and COMT for Treatment Targeting to Positively Impact Quality of LifeR21AG058020 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLELLAND, CATHERINE L · 2018 to 2019
$446k
NCATS NIH HHS UL1 TR001873NIA NIH HHS R21 AG058020
6 · The paper itself

Abstract

backgroundNegative neuropsychiatric symptoms, such as apathy, are a core feature of Alzheimer's disease. Previous studies have shown that levels of fasting plasma proline and differential activity of the catechol-O-methyltransferase (COMT) enzyme, which metabolises dopamine, influence negative symptoms in patients with severe psychiatric illness and those at risk for psychosis. For patients with the COMT high activity enzyme (as assessed via the COMT Val

aimsIn this proof-of-concept cross-sectional study, we tested the hypothesis that proline and COMT Val

methodLeast Absolute Shrinkage and Selection Operator regression was employed to model the interaction between proline and COMT on negative symptoms in

resultsThe proline

conclusionsHigher proline also has opposing effects on negative symptoms by COMT genotype in patients with dementia and further supports the development of therapeutics aimed at modulating this interaction pathway across neuropsychiatric disorders.

Indexed as

Alzheimer’s diseaseCOMTnegative symptomsneuropsychiatryproline

Identifiers

PMID41392765
PMCPMC12724090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.